Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study) - Sorbonne Université
Journal Articles BMJ Open Year : 2023

Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study)

Aurore Dougé
  • Function : Author
Aurélie Ravinet
  • Function : Author
  • PersonId : 1297364
Alexandrine Corriger
Aurélie Cabrespine
  • Function : Author
Mathieu Wasiak
  • Function : Author
Bruno Pereira
  • Function : Author
Harry Sokol
  • Function : Author

Abstract

Allogeneic haematopoietic stem-cell transplantation (allo-HSCT) is a major treatment for many haematological malignancies. The procedure has a good success rate but high transplant-related toxicity (TRM). TRM is mostly related to graft-versus- host disease (GvHD) and infectious complications. Alterations of the intestinal microbiota plays a major role in the development of allo- HSCT complications. The gut microbiota could be restored by faecal microbiota transplantation (FMT). However, there are no published randomised studies assessing the efficacy of FMT for GvHD prophylaxis.
Fichier principal
Vignette du fichier
e068480.full.pdf (457.88 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-04251279 , version 1 (20-10-2023)

Identifiers

Cite

Aurore Dougé, Aurélie Ravinet, Alexandrine Corriger, Aurélie Cabrespine, Mathieu Wasiak, et al.. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study). BMJ Open, 2023, 13 (5), pp.1-10. ⟨10.1136/bmjopen-2022-068480⟩. ⟨hal-04251279⟩
29 View
12 Download

Altmetric

Share

More